Çelebi N - Search Results

1

Formulation Strategies of Nanosuspensions for Various Administration Routes.

Pınar SG, Oktay AN, Karaküçük AE, Çelebi N. Pınar SG, et al. Among authors: celebi n. Pharmaceutics. 2023 May 17;15(5):1520. doi: 10.3390/pharmaceutics15051520. Pharmaceutics. 2023. PMID: 37242763 Free PMC article. Review.

2

A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: Investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats.

Cilek A, Celebi N, Tirnaksiz F, Tay A. Cilek A, et al. Among authors: celebi n. Int J Pharm. 2005 Jul 14;298(1):176-85. doi: 10.1016/j.ijpharm.2005.04.016. Int J Pharm. 2005. PMID: 15950411

3

Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.

Karakucuk A, Celebi N, Teksin ZS. Karakucuk A, et al. Among authors: celebi n. Eur J Pharm Sci. 2016 Dec 1;95:111-121. doi: 10.1016/j.ejps.2016.05.010. Epub 2016 May 13. Eur J Pharm Sci. 2016. PMID: 27181836

4

New perspective to develop memantine orally disintegrating tablet formulations: SeDeM expert system.

Gülbağ S, Yılmaz Usta D, Gültekin HE, Oktay AN, Demirtaş Ö, Karaküçük A, Çelebi N. Gülbağ S, et al. Among authors: celebi n. Pharm Dev Technol. 2018 Jun;23(5):512-519. doi: 10.1080/10837450.2017.1345941. Epub 2017 Jul 18. Pharm Dev Technol. 2018. PMID: 28657404

5

Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.

Oktay AN, Karakucuk A, Ilbasmis-Tamer S, Celebi N. Oktay AN, et al. Among authors: celebi n. Eur J Pharm Sci. 2018 Sep 15;122:254-263. doi: 10.1016/j.ejps.2018.07.009. Epub 2018 Jul 4. Eur J Pharm Sci. 2018. PMID: 29981401

6

Evaluation of improved oral bioavailability of ritonavir nanosuspension.

Karakucuk A, Teksin ZS, Eroglu H, Celebi N. Karakucuk A, et al. Among authors: celebi n. Eur J Pharm Sci. 2019 Apr 1;131:153-158. doi: 10.1016/j.ejps.2019.02.028. Epub 2019 Feb 18. Eur J Pharm Sci. 2019. PMID: 30790704

7

The effect of critical process parameters of the high pressure homogenization technique on the critical quality attributes of flurbiprofen nanosuspensions.

Oktay AN, Ilbasmis-Tamer S, Celebi N. Oktay AN, et al. Among authors: celebi n. Pharm Dev Technol. 2019 Dec;24(10):1278-1286. doi: 10.1080/10837450.2019.1667384. Pharm Dev Technol. 2019. PMID: 31535942

8

Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation.

Tashan E, Karakucuk A, Celebi N. Tashan E, et al. Among authors: celebi n. AAPS PharmSciTech. 2020 Apr 15;21(3):115. doi: 10.1208/s12249-020-01653-9. AAPS PharmSciTech. 2020. PMID: 32296987

9

Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation.

Tashan E, Karakucuk A, Celebi N. Tashan E, et al. Among authors: celebi n. AAPS PharmSciTech. 2020 May 19;21(5):144. doi: 10.1208/s12249-020-01703-2. AAPS PharmSciTech. 2020. PMID: 32430673

10

Investigation of Formulation and Process Parameters of Wet Media Milling to Develop Etodolac Nanosuspensions.

Karakucuk A, Celebi N. Karakucuk A, et al. Among authors: celebi n. Pharm Res. 2020 May 31;37(6):111. doi: 10.1007/s11095-020-02815-x. Pharm Res. 2020. PMID: 32476048

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

183 results

Search Page

Filters